Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial  by Konstan, Michael W. et al.
Journal of Cystic Fibrosis 10 (2011) 54–61
www.elsevier.com/locate/jcfOriginal Article
Safety, efficacy and convenience of tobramycin inhalation powder in cystic
fibrosis patients: The EAGER trial
Michael W. Konstan a,1,⁎, Patrick A. Flume b,1, Matthias Kappler c,1, Raphaël Chiron d,1,
Mark Higgins e,1, Florian Brockhaus f,1, Jie Zhang g,1, Gerhild Angyalosi f,1,
Ellie He g,1, David E. Geller h,1
a Rainbow Babies and Children's Hospital and Case Western Reserve University School of Medicine, Cleveland, OH, United States
b Medical University of South Carolina, Charleston, United States
c Children's Hospital, University of Munich, Munich, Germany
d Hôpital Arnaud de Villeneuve, Montpellier, France
e Novartis Pharmaceuticals Corporation, Horsham, West Sussex, United Kingdom
f Novartis Pharma AG, Basel, Switzerland
g Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
h Nemours Children's Clinic, Orlando, FL, United States
Received 5 August 2010; received in revised form 12 October 2010; accepted 14 October 2010
Available online 12 November 2010Abstract
Background: A light-porous-particle, dry-powder formulation of tobramycin was developed, using PulmoSphere® technology, to improve airway
delivery efficiency, substantially reduce delivery time, and improve patient convenience and satisfaction. We evaluated the safety, efficacy and
convenience of tobramycin inhalation powder (TIP™) versus tobramycin inhalation solution (TIS, TOBI®) for treating Pseudomonas aeruginosa
infection in cystic fibrosis (CF) patients aged ≥6 years.
Methods: In this open-label study, 553 patients were randomized 3:2 to TIP (total 112 mg tobramycin) via the Novartis T-326 Inhaler or TIS
300 mg/5 mL via PARI LC® PLUS nebulizer twice daily for three treatment cycles (28 days on-drug, 28 days off-drug). Safety, efficacy, and
treatment satisfaction outcomes were evaluated.
Results: TIP was generally well-tolerated; adverse events were similar in both groups. The rate of cough suspected to be study drug related was
higher in TIP-treated patients (TIP: 25.3%; TIS: 4.3%), as was the overall discontinuation rate (TIP: 26.9%; TIS: 18.2%). Increases in FEV1%
predicted from baseline to Day 28 of Cycle 3 were similar between groups; the mean reduction in sputum P. aeruginosa density (log10 CFU/g) on
Day 28 of Cycle 3 was also comparable between groups. Administration time was significantly less for TIP (mean: 5.6 versus 19.7 min,
pb0.0001). Treatment satisfaction was significantly higher for TIP for effectiveness, convenience, and global satisfaction.
Conclusions: TIP has a safety and efficacy profile comparable with TIS, and offers a far more convenient treatment option for pseudomonas lung
infection in CF.
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Individuals with cystic fibrosis (CF) are highly susceptible to
endobronchial infection with Pseudomonas aeruginosa (Pa).
For most patients, Pa infections begin in childhood and become
chronic by early adulthood [1]. Chronic Pa infection isd by Elsevier B.V. All rights reserved.
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increased morbidity and mortality [2–5]. Consequently,
effective treatment of Pa infection is crucial to the management
of CF.
Tobramycin inhalation solution (TIS [6]) significantly improves
lung function and quality of life, and reduces hospitalization rates,
in CF patients chronically infected with Pa [7–10]. Current
treatment guidelines recommend TIS for the treatment of chronic
Pa pulmonary infections in CF patients ≥6 years (TOBI®
prescribing information; [11–13]). Administration time is approx-
imately 15–20 min per dose (excluding cleaning and sterilization)
[13].
Treatment of Pa infection by inhaled antibiotics is time
consuming and places a high burden on CF patients; adherence to
treatment is a significant challenge [14–16]. An innovative drug-
device combination using a new dry-powder formulation of
tobramycin has been developed to increase the convenience of
administration for patients, which may increase treatment
adherence and thereby clinical outcomes [17,18]. Tobramycin
inhalation powder (TIP™) is a form of light-porous-particles
that are manufactured using an emulsion-based spray drying
process [19]. TIP is delivered via the T-326 Inhaler (Novartis
Pharmaceuticals Corporation, USA), a dry powder inhaler (DPI).
The device is portable, has no internal or external power source,
and is designed to enhance drug delivery to the lung and shorten
administration time [13]. CF patients as young as 6 years old are
capable of inhaling through a devicewith the internal resistance of
the T-326 Inhaler [20]. Previous studies showed that single-dose
administration of TIP results in more efficient and rapid delivery
of tobramycin than TIS in CF patients, while maintaining similar
pharmacokinetic characteristics [13,21].
The Establish A new Gold standard Efficacy and safety with
tobramycin in cystic fibRosis [EAGER] trial was designed to
evaluate the safety, efficacy and convenience of the new inhaled
formulation of tobramycin (TIP) versus TIS for treating Pa
infection in CF patients.
2. Methods
This international study was conducted in 127 centers in 15
countries and was approved by an Institutional Review Board or
Independent Ethics Committee for each center and was
conducted in accordance with the Declaration of Helsinki.
Written informed consent was obtained from each patient.
2.1. Patients
CF patients aged ≥6 years with forced expiratory volume in
one second (FEV1) ≥25 to ≤75% predicted based on Knudson
equations [22] and sputum or throat cultures positive for Pa
within 6 months of screening (and confirmed at enrollment)
were eligible.
2.2. Study design
This two-arm, randomized, open-label study comprised three
cycles; each cycle consisted of 28 days on-treatment followedby 28 days off-treatment. Total duration of treatment was
24 weeks (Fig. 1A). Eligible patients were randomized 3:2 to
TIP (four capsules/112 mg tobramycin) twice daily adminis-
tered via the T-326 Inhaler, or TIS 300 mg/5 mL (TOBI®) twice
daily administered via the PARI LC® PLUS jet nebulizer and
DeVilbiss PulmoAide compressor or an equivalent alternative.
2.3. Study assessments
Safety assessments included the incidence and intensity of
all adverse events (AEs) and serious AEs (SAEs), presence of
airway reactivity to the drug (post-inhalation drop in FEV1), and
changes in hematology, blood chemistry, urine protein,
audiology, physical condition and body weight.
The main efficacy measure was relative change in FEV1%
predicted from baseline (pre-dose Day 1) at all scheduled post-
treatment visits (Weeks 2, 5, 9, 13, 17, 21 and 25). Other
efficacy measures included change in sputum Pa density (log10
CFU/g sputum), tobramycin susceptibility to Pa (assessed using
minimum inhibitory concentrations [MIC]), antipseudomonal
antibiotic use, and respiratory-related hospitalizations. Serum
and sputum pharmacokinetics were assessed in a subset of the
population.
Patient's self-reported treatment satisfaction was measured
using the Treatment Satisfaction Questionnaire for Medication
(TSQM, a validated instrument) [23], which was modified by
adding four study-specific questions: (I) how convenient or
inconvenient is it to store the medication?; (II) how easy or
difficult is it to put together the parts of the delivery device?;
(III) how convenient or inconvenient would it be to use the
delivery device away from home?; (IV) how convenient or
inconvenient is it for you to take care of the delivery device?
(Note: the standard fourteen questions of the TSQM were not
altered). The TSQM domain scores were calculated as
recommended by the instrument authors; described in detail
elsewhere [23]. The TSQM domain scores range from 0 to 100
with higher scores representing higher satisfaction for that
domain. The term ‘medication’ includes the combination of the
medication and delivery device (aerosol machine/nebulizer or
inhaler).
2.4. Statistical analyses
Sample size was based on the primary variable, safety;
inclusion of 300 TIP patients was estimated to provide a 99.8%
chance of observing at least one AE with a true incidence of 2%
in the TIP group. Inclusion of 500 patients in total (TIP: 300;
TIS: 200) would provide 96% power to demonstrate non-
inferiority of TIP to TIS with regard to relative change from
baseline in FEV1% predicted after three cycles, based on a non-
inferiority margin of 6% and a one-sided significance level of
0.15 (assuming 1% true TIS–TIP treatment difference, and 20%
standard deviation).
The primary objective was to evaluate the safety of TIP
versus TIS (data are summarized descriptively). A pre-planned
non-inferiority analysis compared the efficacy of TIP versus
TIS, with regard to relative change in FEV1% predicted from
Fig. 1. Study design (A) and disposition (B).
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hoc sensitivity analyses assessed the impact of patient
discontinuation. All randomized patients who received ≥1
dose of study drug were included in the safety and efficacy
populations.
3. Results
A total of 553 patients were randomized; 517 received at
least one dose of study medication and were included in the
efficacy and safety populations. Baseline demographic and
clinical characteristics were similar in the two treatment groups
(Table 1). Use of TIS prior to screening was similar in both
groups (TIP: 82.1%; TIS: 82.3%). Concomitant therapy was
used by 99.7% of TIP-treated and 99.0% of TIS-treated patients.
The main cause for discontinuation was AEs (Fig. 1B); more
patients were discontinued in Cycle 1 than in Cycles 2 and 3 for
both groups. Adherence to therapy (based on the number ofdoses actually received versus the possible maximum) was
generally high (N90% of doses) over all three cycles in both
groups. All patients who completed the study without major
protocol deviations were included in the per protocol (PP)
population (TIP: 60.8%; TIS: 66.5%); failure to take at least 80%
of the study drug was the most frequent reason for exclusion.
3.1. Safety
A higher percentage of TIP- than TIS-treated patients
reported AEs (90.3% versus 84.2%, pb0.05) (Table 2). Most
AEs were mild or moderate in intensity (TIP: 73.4%; TIS:
68.5%). The percentage of patients with AEs was highest in
Cycle 1, in both groups (77.9% versus 66.5%), and decreased
with each successive cycle (Cycle 2: 67.0% versus 66.3%;
Cycle 3: 65.8% versus 58.5%).
Cough (not including productive cough) was the most
frequently reported AE throughout the entire study period (TIP:
Table 1
Baseline demographic and clinical characteristics (safety population).
TIP (n=308) TIS (n=209)
Age (years), mean (SD) 26 (11.4) 25 (10.2)
Age group, n (%)
≥6 to b13 years 28 (9.1) 18 (8.6)
≥13 to b20 years 66 (21.4) 48 (23.0)
≥20 years 214 (69.5) 143 (68.4)
Sex, n (%)
Males 171 (55.5) 115 (55.0)
Females 137 (44.5) 94 (45.0)
Race, n (%)
Asian 2 (0.6) 2 (1.0)
Black 3 (1.0) 1 (0.5)
Caucasian 279 (90.6) 189 (90.4)
Hispanic 20 (6.5) 17 (8.1)
Other 4 (1.3) 0 (0.0)
Region, n (%)
North America 195 (63.3) 131 (62.7)
Europe and rest of world a 104 (33.8) 71 (34.0)
Latin America 9 (2.9) 7 (3.4)
Body mass index (kg/m2), mean (SD) 20.7 (4.0) 20.4 (3.5)
Screening FEV1% predicted, n (%)
b
≥25 to b50% 128 (41.6) 89 (42.6)
≥50 to b75% 180 (58.4) 120 (57.4)
Baseline FEV1% predicted, mean (SD)
b 53 (14.2) 53 (15.9)
Chronic macrolide use, n (%) 187 (60.7) 125 (59.8)
Last use of antipseudomonal antibiotics prior to first dose (month), n (%)
=1 78 (25.3) 46 (22.0)
N1–3 171 (55.5) 112 (53.6)
N3–6 33 (10.7) 24 (11.5)
N6 11 (3.6) 9 (4.3)
Never used 15 (4.9) 18 (8.6)
P. aeruginosa tobramycin MIC, n (%) c
N8 μg/mL 68 (22.1) 48 (23.0)
a Rest of world including Australia and Israel.
b Randomization is based on screen FEV1% predicted. Baseline FEV1 was
defined as the last measurement prior to the first dose of study drug.
c Maximum MIC of all P. aeruginosa phenotypes; TIP = tobramycin
inhalation powder; TIS = tobramycin inhalation solution; SD = standard
deviation; FEV1 = forced expiratory volume in one second; MIC = minimum
inhibitory concentration.
Table 2
Most common (≥5% in any group) adverse events occurring in Cycles 1–3
(safety population).
n (%) TIP (n=308) TIS (n=209)
Any adverse event 278 (90.3) 176 (84.2)
Cough 149 (48.4) 65 (31.1)
Lung disorder a 104 (33.8) 63 (30.1)
Productive cough 56 (18.2) 41 (19.6)
Dyspnea 48 (15.6) 26 (12.4)
Pyrexia 48 (15.6) 26 (12.4)
Oropharyngeal pain 43 (14.0) 21 (10.5)
Dysphonia 42 (13.6) 8 (3.8)
Hemoptysis 40 (13.0) 26 (12.4)
Headache 35 (11.4) 25 (12.0)
Nasal congestion 25 (8.1) 15 (7.2)
Nausea 23 (7.5) 20 (9.6)
Rales 22 (7.1) 13 (6.2)
Rhinorrhea 22 (7.1) 15 (7.2)
Pulmonary function test decreased 21 (6.8) 17 (8.1)
Upper respiratory tract infection 21 (6.8) 18 (8.6)
Wheezing 21 (6.8) 13 (6.2)
Chest discomfort 20 (6.5) 6 (2.9)
Fatigue 20 (6.5) 10 (4.8)
Vomiting 19 (6.2) 12 (5.7)
Sinusitis 18 (5.8) 15 (7.2)
Pulmonary congestion 17 (5.5) 9 (4.3)
TIP = tobramycin inhalation powder; TIS = tobramycin inhalation solution.
a Lung disorders were generally reported by the investigator as a pulmonary
or cystic fibrosis exacerbation.
57M.W. Konstan et al. / Journal of Cystic Fibrosis 10 (2011) 54–6148.4%; TIS: 31.1%). As a baseline symptom, cough was present
in a high proportion of patients (42%) in both groups. Most
cough events were mild or moderate in intensity. The frequency
of severe cough events was low and balanced between groups
(2.6% versus 1.9%). Less than 4% (12/308) of TIP-treated
patients discontinued due to cough versus 1% (2/209) of TIS-
treated patients. Cough events were suspected by the investi-
gator as being related to study drug in 25.3% and 4.3% of
patients in the TIP and TIS group, respectively. Other treatment-
related AEs more commonly reported in the TIP group were
dysphonia (13.6% versus 3.8%) and dysgeusia (3.9% versus
0.5%).
Clinically significant bronchospasm (defined as an acute
relative change of≥20% decrease in FEV1% predicted from pre-
dose to 30-minute post-dose) in any cycle was experienced by
5.2% and 5.3% of TIP- and TIS-treated patients, respectively.
The incidence of SAEs was similar in both groups (TIP:
27.4%; TIS: 29.2%). Lung disorders were the most commonly
reported SAE in both groups (TIP: 19.5%; TIS: 18.7%). SAEswere reported by fewer patients in both groups, with each
successive treatment cycle (Cycle 1: 15.5%; Cycle 2: 9.3%; and
Cycle 3: 7.4%). Three deaths were reported during the study.
All were in the TIP group, although none was related to the
study drug.
Therewere no clinically relevant changes from baseline to pre-
specified time points for vital signs, and biochemical or
hematological measures. There were few reports (≤4%) of
renal function changes as measured by increases in serum
creatinine, blood urea nitrogen, or proteinuria in both groups. The
incidence of AEs related to renal and urinary disorders, including
proteinuria, dysuria, polyuria and nephrolithiasis, was ≤1% in
both groups.
Audiology was performed in a subpopulation of patients
(TIP: 78 [25.3%]; TIS: 45 [21.5%]). Twenty (25.6%) TIP-
treated and 7 (15.6%) TIS-treated patients experienced a
decrease from baseline in any audiology test frequency at any
visit; the decrease was of a similar degree in both groups. Using
the criteria for either ear of 10 dB loss at three consecutive
frequencies, 15 dB loss at two consecutive frequencies and
20 dB loss at any frequency, 3 (0.97%) TIP-treated and 2
(0.96%) TIS-treated patients were considered to have clinically




Increases in FEV1% predicted from baseline to Day 28 of
Cycle 3 were similar between groups (least squares [LS] mean
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limit (−0.67%) of the one-sided 85% [CI] (equivalent to 70%
two-sided) was within the predefined 6% margin for predefined
non-inferiority indicating that TIP was non-inferior to TIS. LS
mean values from the PP population supported this analysis (LS
mean difference in FEV1 of 1.2%, lower limit of the one-sided
85% CI was −1.02%).
3.2.2. Microbiology
Mucoid and non-mucoid Pa sputum densities showed a
decrease from baseline in both groups at all time points (Fig. 2B
presents combined mean of all phenotypes). The mean change
from baseline was greater in the TIP versus TIS group on Day
28 of Cycle 3 (mean change: −1.6 versus −0.92 log10 CFU/g
for mucoid phenotype and −1.77 versus −0.73 log10 CFU/g for
non-mucoid phenotype, respectively). On Day 28 of Cycle 3,
11.6% of TIP and 9.9% of TIS patients had negative Pa
cultures.
The MIC of tobramycin against Pa increased from baseline
to Day 28 of Cycle 3 in both groups (≥4-fold increase: 67/199
[33.7%] versus 42/154 [27.3%]; ≥2-fold increase: 97/199Fig. 2. Overall efficacy: A) relative change in FEV1% predicted from baseline over t
aeruginosa sputum density (efficacy population).[48.7%] versus 61/154 [39.6%]).For patients with Pa isolates
(all phenotypes) with an MIC b8 μg/mL at baseline (TIP,
22.1%; TIS, 23.0%), 19.1% versus 14.9% of TIP- and TIS-
treated patients had an MIC N8 μg/mL at the end of Cycle 3.
3.2.3. Antipseudomonal antibiotic use and hospitalizations
The proportion of patients requiring any new antipseudo-
monal antibiotic was significantly higher with TIP than TIS
(64.9% versus 54.5%, p=0.0148). However, the average
number of days of antibiotic usage tended to be less in the
TIP group (mean [SD]: 30.9 [23.34] versus 33.4 [24.42] days,
p=0.2039). Most newly used antibiotics were administered
orally; oral antibiotics were used in 55.5% and 39.7% of
patients in the TIP and TIS groups, respectively. Ciprofloxacin
was the most frequently used new anti-pseudomonal antibiotic
during the study (47.7% versus 34.0%).
The number of patients hospitalized for respiratory-related
events was similar in the TIP versus TIS group (24.4% versus
22.0%). The proportion of hospitalized patients receiving
antibiotics (excluding inhaled antibiotics) was well matched
between groups (22.1% versus 21.5%).hree cycles (efficacy population); and B) change from baseline in Pseudomonas
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Mean duration of administration was significantly less for
TIP (5.6 min) than TIS (19.7 min, excluding cleaning and
sterilization) at each study visit and overall ( pb0.0001).
3.2.5. Patient-reported treatment satisfaction
Overall, patient satisfaction was higher with TIP (Table 3).
LS mean scores were significantly higher ( pb0.0001) with TIP
than TIS at all visits for effectiveness (a higher score indicates
higher satisfaction for that domain); this takes into account
patients' assessment of the ability of their medication to treat or
prevent their condition and relieve symptoms, as well as the
time it takes to start working. Patients also reported treatment
with TIP to be significantly more convenient than TIS for the
entire study ( pb0.0001); this takes into account patients'
assessment of the overall convenience of treatment (e.g. ease of
use and time). Furthermore, global satisfaction was reported to
be statistically greater for TIP than TIS at all visits ( p=0.0018).
No difference in side effect ratings (patients' assessment of how
bothersome the side effects are and their perception of the
impact of the side effects on their physical and mental abilities)
was reported between groups during the study ( p=0.6833). The
four supplementary questions relating to the use and mainte-
nance of the inhalation devices (i.e. storage, device assembly,
use of device away from home and device caretaking) all
showed a significant difference in favor of TIP for the entire
study period ( pb0.0001).
3.2.6. Pharmacokinetics
Pharmacokinetic assessments were performed in 30 TIP-
treated and 14 TIS-treated patients. Serum tobramycin concentra-
tions were comparable for TIP and TIS. Sputum levels were
generally higher for TIP 30-minute post-dose (mean±SD on Day
28, Cycle 3: TIP, 1979±2770 μg/g; TIS, 1074±1182 μg/g). At
baseline, more than 91.2% of TIP patients had Pa isolates with an
MIC at least 20 times lower (64 μg/mL or less) than the mean
sputum concentration observed within 30 min of the first dosing
in Cycle 1. At the end of Cycle 3, 86.4% of TIP patients had Pa
isolates (all phenotypes) with an MIC at least 30 times lower
(64 μg/mL or less) than the mean sputum concentration observed
30-minute post-dose.Table 3
Patient-reported treatment satisfaction from modified Treatment Satisfaction
Questionnaire for Medication (safety population).






TIP (n=308) TIS (n=209)
Effectiveness 74.8 65.4 9.36 (1.460) b0.0001
Side effects 92.1 92.6 −0.50 (1.218) 0.6833
Convenience 82.7 58.4 24.35 (1.547) b0.0001
Global satisfaction 76.2 71.0 5.20 (1.655) 0.0018
LS mean = least squares mean; TIP = tobramycin inhalation powder; TIS =
tobramycin inhalation solution; SE = standard error. LS mean difference (TIP–
TIS), and p values are calculated from repeated measures model with treatment,
baseline FEV1% predicted, age, chronic macrolide use, region, visit, visit-by-
treatment interaction in the model. A higher score indicates higher satisfaction
for that domain.4. Discussion
This study demonstrates that the safety profile of a new drug-
device combination of TIP delivered via the T-326 Inhaler, is
similar to TIS, especially with regard to systemic safety. The
results of safety analyses are supportive of previously published
reports showing an acceptable safety profile for TIP, which is
generally well-tolerated in most patients with CF [13,18].
The dose of TIP (112 mg tobramycin) used in this study was
chosen based on a previous study that showed it is pharmaco-
kinetically equivalent to the licensed formulation of TIS (TOBI®)
[16]. In the present study, pharmacokinetic analysis confirmed
that serum tobramycin concentrations were comparable for TIP
and TIS post-inhalation. Importantly, systemic levels were low
relative to those associated with producing toxicity with
intravenous tobramycin (10–12 μg/mL) [24].
AEs were similar in both groups; except for the incidence of
cough, dysphonia and dysgeusia, which was higher in patients
receiving TIP. Cough is a frequent event with all inhaled
therapies [13]. It is possible that the comparatively high powder
‘payload’ may underlie the higher reported cough rate in TIP-
versus TIS-treated patients (as well as the local effect of
dysphonia and dysgeusia). It is unclear if the high level of prior
TIS use in these patients and the open-label design had an
influence on the propensity to report cough as an AE for each
treatment. Most cough events were mild or moderate in
intensity in both groups. The frequency of cough was similar
in patients using TIP, regardless of lung disease severity at
baseline. While the majority of patients in the study were adults,
it appeared that children and adolescents tended to cough more
with TIP than adults, whereas the opposite was true for TIS.
However, none of the children discontinued TIP treatment due
to cough events. Cough in the absence of other AEs (i.e. cough
not associated with other features suggestive of an exacerba-
tion) led to discontinuation of five of the 308 patients
randomized to TIP. Post-hoc analyses showed that cough did
not appear to be related to bronchospasm; additionally, the
number of patients experiencing a ≥20% decline in FEV1%
predicted within 30-minute of inhalation was similar in both
groups. The incidence of SAEs was similar in TIP- and TIS-
treated patients. TSQM side effect ratings showed no difference
between groups, indicating that unwanted effects of TIP and
TIS had a similar impact on patients' lives.
The overall discontinuation rate was higher with TIP
(26.9%) than TIS (18.2%); however, there is no clear reason
for the difference in discontinuation rates between groups. The
main reason for discontinuation in both groups was an AE; most
frequently cough and lung disorders (reported as pulmonary or
CF exacerbations), although relatively few patients in either
group discontinued due to cough or lung disorders.
The present study was also powered to assess the non-
inferiority of TIP to TIS with regards to efficacy. The pre-
planned efficacy analyses show that TIP was not inferior to TIS,
in terms of maintenance of lung function. Importantly, the
difference in discontinuation rates did not influence the non-
inferiority conclusion, based on various sensitivity analyses.
The results support those of a recent placebo-controlled trial that
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[21].
In accordance with previous studies [6,17], TIP and TIS both
decreased sputum Pa densities (mucoid and non-mucoid
phenotypes). Conversely, MICs increased from Days 1 to 28
in all 3 cycles. Exposure of bacterial populations to antibiotics
may select for microbes with reduced susceptibility to these
drugs over time [25]. However, tobramycin susceptibility
thresholds with parenteral administration might not be relevant
to inhaled therapy, as drug concentrations achieved at the site of
infection with inhaled antibiotics, including tobramycin, can be
significantly higher than systemic concentrations [13]. At the
end of Cycle 3, most TIP patients (86.4%) had an MIC at least
30 times lower than the mean sputum concentration observed
30-minute post-dose. The results of the pharmacokinetic
analyses also showed that sputum concentrations were
generally greater for TIP; however, the level of inter-subject
variability was high, similar to previous studies. Based on these
data we can conclude that TIP administration appears to result
in lung exposure that is comparable to TIS.
The use of new anti-pseudomonal antibiotics was signifi-
cantly greater in TIP- versus TIS-treated patients during the
study. The difference does not appear to have been driven by
events of a higher clinical intensity. In both groups, the majority
of newly used anti-pseudomonal antibiotics were oral, with
ciprofloxacin the most frequently used. These data suggest the
difference is largely driven by oral ciprofloxacin use for milder
events (i.e. those not needing intravenous antibiotics and/or
hospitalization). It is possible that the higher incidence of cough
in the TIP group may have driven the greater use of other
antibiotics. Again, the influence of the open-label design cannot
be excluded. Post-hoc sensitivity analyses suggest that the use
of new anti-pseudomonal antibiotics did not alter the conclusion
regarding the non-inferior efficacy of TIP versus TIS.
Delivery of antibiotics via inhalation is an attractive option
for treating chronic lung infection in CF patients. However,
aerosolized antibiotics such as TIS require a compressor and
nebulizer, and are associated with prolonged drug administra-
tion times [13]. TIS is approved for use with the PARI LC®
PLUS nebulizer only, which requires 15–20 min to nebulize a
dose. Faster nebulizers than the PARI LC® PLUS have been
developed since the approval of TIS and are available in some
countries; however, they have not been adequately studied to
demonstrate efficacy and safety with TIS. In the present study,
administration times for TIP were approximately 14 min faster
than TIS (excluding time required to set up, clean and disinfect
the TIS nebulizer), consistent with previously reported
administration times [13]. This resulted in a 28-minute saving
per day, equivalent to 13 h per 4-week cycle, in addition to the
reduced time required to set up and clean the T-326 Inhaler
versus the PARI LC® PLUS nebulizer and compressor.
Reducing administration time may have beneficial effects on
adherence and clinical outcomes. The ease of use and
convenience of TIP were highlighted in the treatment
satisfaction responses obtained via the TSQM. Mean patient
assessments for effectiveness, convenience and global satisfac-
tion domains were significantly greater for TIP than TIS;importantly, this difference was sustained over the course of the
study. The four additional questions relating to the use and
maintenance of the inhalation devices also showed a significant
difference in favor of TIP.
In summary, the safety profile of TIP was comparable with
the currently approved formulation of tobramycin, TIS, with the
exception of cough, dysphonia and dysgeusia. Patient-reported
satisfaction was significantly higher with TIP than TIS, which
was related to the ease of use and convenience of TIP.
Importantly, non-inferiority was demonstrated for TIP with
regard to efficacy. Thus, the new drug-device combination for
TIP could offer CF patients a much more convenient option for
treating Pa infections, without compromising safety or efficacy.
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